Compact base editing brings a one-vector DMD strategy closer to muscle tissue
Duchenne muscular dystrophy (DMD) remains one of the clearest examples of how a single-gene defect can drive relentless multisystem injury. Large deletions in the DMD gene remove dystrophin, leaving skeletal muscle and the heart vulnerable to progressive damage. This study pursued a different repair logic: instead of replacing the entire gene, investigators used adenine base editing to alter splice acceptor sites and force exon skipping, with the goal of restoring the reading frame and allowing dystrophin production to resume.
The technical challenge has been considerable. Conventional adeno-associated virus delivery is constrained by packaging capacity, and high systemic doses raise toxicity concerns, especially when the liver becomes a major off-target organ. Here, a compact editor called SlugABE8e was paired with a single-guide RNA inside one AAV vector, creating an all-in-one construct that could be delivered systemically. The work also explored a muscle-tropic MyoAAV4 capsid, a key design choice because efficient muscle delivery is only half the problem; avoiding unwanted hepatic uptake is the other half.
In cell-based screening, 87 compact editor and guide combinations were tested in HEK293T cells, and the editing readout was assessed by Sanger sequencing three days after transfection. The screen was not merely a feasibility exercise. It identified a workable molecular route for a mutation class that, in principle, could be addressed through splice-site rewriting rather than gene replacement. For DMD, where the underlying pathology is the absence of functional dystrophin at the sarcolemma, any strategy that re-establishes the open reading frame can shift muscle cells away from constant mechanical injury.
Dystrophin returned in heart and skeletal muscle after systemic MyoAAV4A delivery
The most consequential findings came from the humanized DMD mouse model. Systemic delivery of MyoAAV4A in juvenile DMD mice efficiently restored dystrophin expression in both the heart and skeletal muscles. In a disease defined by cardiac and skeletal muscle failure, dual-tissue rescue matters because isolated improvement in one compartment would leave the overall phenotype only partially addressed. Dystrophin restoration in both tissues suggests the editor and capsid together achieved biologically meaningful distribution, not just molecular activity in a narrow target zone.
The molecular correction was accompanied by lower serum creatine kinase activity, a familiar marker of muscle injury in dystrophic disease. Reduced creatine kinase implies less membrane disruption and less leakage of intracellular contents into the circulation, a direct readout of improved myofiber stability. Muscle pathology also diminished, reinforcing the view that gene correction translated into structural benefit rather than a purely laboratory-level editing signal.
One sentence captures the practical consequence: the edited muscle looked and behaved less like dystrophic tissue.
Because the strategy depends on a permanent sequence change at the splice acceptor site, the biological appeal is durable exon skipping rather than transient pharmacologic modulation. In a condition where repeated dosing would be cumbersome and where the target tissue is dispersed throughout the body, one durable correction event has obvious therapeutic logic. The study does not claim clinical readiness, but it does show that a compact, single-vector base editor can operate in vivo at a dose low enough to make systemic delivery more plausible than earlier large-cargo approaches.
Liver detargeting and editor fidelity shaped the safety profile
The liver remained central to the design problem, and the investigators addressed it directly with a liver-detargeted MyoAAV4E-off capsid. This capsid eliminated viral entry and editing in the liver, a meaningful advance because hepatic exposure has been a persistent obstacle for AAV-based gene delivery. Avoiding the liver is not a cosmetic optimization; it reduces the chance that the vector will be sequestered away from muscle and may lower the toxic burden associated with high-dose systemic administration.
The study also tested SlugHF-ABE8e(V106W), a high-fidelity base editor, and found similar on-target and off-target editing compared with SlugABE8e. That result is important for translational planning because precision editing cannot succeed on efficacy alone. If a therapeutic editor corrects the intended nucleotide while introducing avoidable collateral changes, the long-term risk profile becomes harder to justify. The available data here suggest the higher-fidelity variant did not sacrifice the editing behavior needed for dystrophin rescue, although the abstract does not provide a full off-target map or long-term safety follow-up.
For DMD patients, the main barrier has never been a shortage of genetic targets. It has been a delivery system that can reach muscle broadly, avoid the liver, fit within AAV cargo limits, and perform a correction sturdy enough to matter biologically. This study advances all four demands in a single construct: a compact adenine base editor, an sgRNA, a muscle-tropic capsid, and a liver-detargeted option. The work therefore points to a realistic engineering path for exon-skipping gene correction in a disease where even partial dystrophin restoration can alter the trajectory of muscle degeneration.
Still, the evidence stops at the humanized mouse stage. The abstract does not report long-term durability, immune consequences, or dose-ranging safety data in a clinical setting. It also does not establish how many human DMD genotypes would be directly addressable by this exact exon-skipping design. Those unanswered questions define the next barrier between a compelling molecular repair strategy and a therapy that can be carried into patients with confidence.